receptor phosphorylation by AEE788 reduces growth and metastasis of
human colon carcinoma in an orthotopic nude mouse model. Cancer
Res 65, 3716 – 3725. [31]
[18] Yigitbasi OG, Younes MN, Doan D, Jasser SA, Schiff BA, Bucana CD,
Bekele BN, Fidler IJ, and Myers JN (2004). Tumor cell and endothelial
cell therapy by dual tyrosine kinase receptor blockade. Cancer Res 64,
7977 – 7984. [32]
[19] Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, and Fidler IJ
(2003). Blockade of epidermal growth factor receptor signaling in tumor
cells and tumor-associated endothelial cells for therapy of androgenindependent human prostate cancer growing in the bone of nude mice.
Clin Cancer Res 9, 1200 – 1210. [33]
[20] Baker CH, Kedar D, McCarty MF, Tsan R, Weber KL, Bucana CD, and
Fidler IJ (2002). Blockade of epidermal growth factor receptor signaling
on tumor cells and tumor-associated endothelial cells for therapy of
human carcinomas. Am J Pathol 161, 929 – 938.
[21] Langley RR, Ramirez KM, Tsan RZ, Van Arsdall M, Nilsson MB, and [34]
Fidler IJ (2003). Tissue-specific microvascular endothelial cell lines
from H-2Kb-tsA58 mice for studies of angiogenesis and metastasis.
Cancer Res 63, 2971 – 2976.
[22] Langley RR, Fan D, Tsan RZ, Rebhun R, He J, Kim SJ, and Fidler IJ [35]
(2004). Activation of the platelet-derived growth factor-receptor en- hances survival of murine bone endothelial cells. Cancer Res 64,
3727 – 3730.
[23] Traxler P, Buchdunger E, Furet P, Gschwind H-P, Ho P, Mett H, O'Reilly T,
Pfaar U, and Thomas H (1999). Preclinical profile of PKI166: a novel and [36]
potent EGF-R tyrosine kinase inhibitor for clinical development.
Clin Cancer Res 5, 3750s.
[24] Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J,
Rooney DL, Ihrig MM, McManus MT, Gertler FB, et al. (2003). A lentivirus-based system to functionally silence genes in primary mammalian [37]
cells, stem cells and transgenic mice by RNA interference. Nat Genet
33, 401 – 406.
[25] Cheng H, Cenciarelli C, Nelkin G, Tsan R, Fan D, Cheng-Mayer C, and [38]
Fidler IJ (2005). Molecular mechanism of hTid-1, the human homolog of
Drosophila tumor suppressor l(2)Tid, in the regulation of NF-nB activity [39]
and suppression of tumor growth. Mol Cell Biol 25, 44 – 59.
[26] Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley RR,
and Fidler IJ (2002). Contributions of stromal metalloproteinase-9 to [40]
angiogenesis and growth of human ovarian carcinoma in mice. J Natl
Cancer Inst 94, 1134 – 1142.
[27] Gold DP, Clevers H, Alarcon B, Dunlap S, Novotny J, Williams AF, and [41]
Terhorst C (1987). Evolutionary relationship between the T3 chains of
the T-cell receptor complex and the immunoglobulin supergene family.
Proc Natl Acad Sci USA 84, 7649 – 7653.
[28] Herbst RS, Fukuoka M, and Baselga J (2004). Gefitinib—a novel tar- [42]
geted approach to treating cancer. Nat Rev Cancer 4, 956 – 965.
[29] Stetler-Stevenson WG (1999). Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest
103, 1237 – 1241. [43]
[30] Hida K and Klagsbrun M (2005). A new perspective on tumor endothe-
